METTL2B m3C RNA transferase: oncogenic role in ovarian cancer progression via regulation of the mTOR/AKT pathway and its link to the tumor immune microenvironment Authors: Yizi Meng, Yimei Meng, Hui Zheng, Jinru Huo, Peiling Li, Yanhong Shan, Jin He Published: 2024 ABSTRACT BackgroundAberrant expression of N3-methylcytidine methyltransferase 2B (METTL2B) has been observed in various human malignancies, including those of the prostate, liver, breasts, and bladder. However, its role in ovarian cancer (OC) remains largely unexplored. This research preliminarily investigated METTL2B expression in OC and elucidated the associated molecular mechanisms.MethodsWe utilized three publicly available cancer-related databases (Genotype-Tissue Expression, Gene Expression Omnibus, and The Cancer Genome Atlas) to identify gene signatures in patients with OC and normal individuals with a specific focus on METTL2B. The role of METTL2B in OC was evaluated using patient survival data, and its impact on oncogenic behaviors in both cell and animal models, including growth potential, migration, invasion, and the tumor microenvironment, was examined. This assessment was conducted using bioinformatics tools such as Gene Set Cancer Analysis, GeneMANIA, and Tumor Immune Single-cell Hub 2. Additionally, the association between drug sensitivity and METTL2B expression was analyzed using CellMiner.ResultsMETTL2B expression was significantly elevated in OC, highlighting its potential clinical value in the diagnosis and prognosis of OC. Patients with lower METTL2B expression exhibited favorable survival. Furthermore, METTL2B knockdown significantly disrupted oncogenic behaviors in OC cell lines by suppressing the mTOR/AKT signaling pathway. Additionally, bioinformatics-based Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses suggested a close correlation between METTL2B and immune responses.ConclusionsOur research confirmed the upregulation of METTL2B in OC, suggesting its oncogenic function. However, METTL2B expression was negatively correlated with the infiltration scores of multiple immune cells, including cytotoxic cells and T cells, indicating its complex role in the tumor immune microenvironment. These findings highlight the significant clinical value of METTL2B in the diagnosis and prognosis of OC.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12885-024-13225-2. Background Ovarian cancer (OC) is one of the most life-threatening diseases globally among women older than 40, and it is the second most prevalent type of malignancy in the female population [1]. Global Cancer Statistics 2020 recorded an estimated 313,959 new cases of OC, accounting for 1.6% of all new cancer cases. With 207,252 recorded deaths, OC ranks as the eighth most life-threatening malignancy worldwide [2]. To date, there are numerous therapeutic treatments for OC including surgery, platinum–taxane chemotherapy [3], targeted therapy [4–8], immunotherapy, and combination strategies [9]. The AKT/mTOR pathway is crucial in OC because of its involvement in tumor invasion and metastasis. Remarkably, the AKT/mTOR pathway was found to be abnormally activated in 70% of patients with OC [10]. This finding provided a basis for combination therapy with first-line anti-cancer therapeutic agents alongside mTOR pathway inhibitors, such as everolimus and temsirolimus [11]. Despite continuous advances in the treatment of OC, overall response rates remain limited. Consequently, the development of reliable indicators for predicting outcomes is urgently needed to better guide treatment strategies for OC. Epigenetic modifications have garnered increased attention, particularly in the area of RNA modification, because of the emergence of several high-tech and advanced methods such as high-throughput sequencing. Among these, methylation is the most abundant RNA modification. Growing evidence has linked RNA methylation to various human diseases, including cancers [12]. Several eukaryotic RNA modifications are commonly found in the human body, including m6A, m5C, m3C, m1A, and 7G. Recent studies revealed vital roles of m6A [13–16], m5C [17, 18], and m1A [19] in tumor growth, metastasis, recurrence, and drug resistance in OC. However, it remains unclear whether the m3C modification plays a crucial role in tumorigenesis and cancer development. The methyltransferase-like protein (METTL) family, comprising four members, namely METTL2A, METTL2B, METTL6, and METTL8, is involved in the m3C modification [20]. Among these proteins, METTL6 has been linked to prognosis in several malignancies across various body systems, including the lungs, breasts, and liver [21–23]. Additionally, the methyltransferase activity of METTL8 is enhanced by SUMOylation, leading to R-loop formation and m3C methylation. This process promotes colorectal malignancies [24]. Although oncogenic roles have been reported for other m3C modifiers such as METTL6 and METTL8, functional exploration of METTL2B in OC has been limited. This gap in the literature presents an opportunity to contribute fresh insights into the understanding of OC biology. Therefore, we investigated the role of METTL2B in OC using a bioinformatics strategy, evaluated its impact on oncogenic behavior using both in vitro and in vivo OC models, and explored its association with the tumor immune microenvironment. Our research found aberrantly elevated METTL2B expression in patients with OC, and its expression was correlated with unfavorable survival outcomes and local immune cell infiltration. This suggests that METTL2B could represent a promising treatment target in OC. Materials and methods Data acquisition In this study, clinical data were sourced from OC datasets within TCGA. Gene expression profiles for healthy individuals were obtained from GTEx Portal, a comprehensive public repository of normal tissue and cell-specific gene expression information. The count data contain 60,499 identifiers and 19,109 samples, including 88 normal ovarian samples from GTEx and 427 OC samples from TCGA. In addition to the two aforementioned databases, further information, including data within GSE54388, was obtained from GEO. The raw data extracted from the online databases were subjected to batch processing and normalization with the R package “limma.” The expression pattern of METTL2B in OC The differences in ovarian METTL2B expression patterns between patients with OC and healthy individuals, as sourced from the aforementioned publicly available databases, were identified through statistical analyses, including the signed-rank test and Wilcoxon’s rank-sum test. Survival analysis The survival of patients with OC was assessed using Kaplan–Meier survival curves and statistical analysis such as the log-rank test. Correlation between METTL2B expression and its CNV In this study, the correlation between METTL2B expression in OC and CNV was evaluated using GSCA database, which integrates multiple genomic data across various cancer types from TCGA (http://bioinfo.life.hust.edu.cn/GSCA/) [25]. Functional enrichment analysis A common computational method, namely GSEA, has been used to analyze large biological datasets. By utilizing gene sets from GO and KEGG, GSEA helps to interpret the biological significance of observed changes in gene expression, linking them to known biological processes and pathways. This analysis began by obtaining the “c2 KEGG gene set” and “c2 REACTOME gene set” GMT files from the MSigDB database. Subsequently, GSEA was conducted by focusing on three gene sets using the R package “clusterProfiler” with threshold criteria set at P < 0.05 and FDR < 0.1. This approach will help us gain a more comprehensive understanding of the functional regulatory mechanisms of METTL2B in OC development. Stromal and immune scores in tumor samples The gene signatures of patients with OC, including the METTL2B expression profile in each tumor sample, were identified. Based on these gene expression data, the stromal and immune scores were calculated using ESTIMATE algorithm with the ssGSEA method included in the R package “GSVA” [26]. These scores reflect tumor purity, the presence of stromal cells, and the infiltration level of immune cells in tumor tissues. Top 20 hub genes associated with METTL2B GeneMANIA is a bioinformatics tool that can identify other genes associated with a set of input genes based on tumor functional association data such as protein and genetic interactions, pathways, co-expression, co-localization, and protein domain similarity. The key selection parameters for the top 20 hub genes included protein–protein interactions (based on experimental data), genetic interactions (involving shared biological pathways), co-expression evidence (reflecting similar gene expression patterns), co-localization (genes located in the same chromosomal region), and shared protein domains (indicating related functions). These criteria were integrated by the GeneMANIA algorithm, allowing us to select the 20 hub genes most highly associated with METTL2B based on their network association scores. The network of those hub genes was visualized using Cytoscape, an open source software platform for visualizing complex networks. TISCH2 database Analysis of the tumor microenvironment (TME) was conducted using TISCH2, an scRNA-seq database focusing on the TME [27]. We explored the expression of METTL2B in each subpopulation after identifying detailed cellular subpopulations by clustering six OC tissues in the GSE147082 dataset through the TISCH2 database. Prediction of drug sensitivity in patients with OC The correlation between drug sensitivity (FDA-approved chemotherapeutic agents) and METTL2B expression in patients with OC was investigated using the CellMiner database [28], which links gene expression data to drug response profiles from the NCI-60 cell line panel. The methodology involved analyzing the mRNA expression of METTL2B, correlating the findings with the sensitivity of OC cells to FDA-approved chemotherapeutic agents. A comprehensive statistical correlation analysis was performed, considering clinical parameters such as the mechanism of action, target enzymes, and genetic interactions. Through this approach, we identified significant correlations between METTL2B expression and drug sensitivity, suggesting that patients with high METTL2B expression exhibit increased sensitivity to chemotherapy and offering new insights into potential therapeutic targets for OC. Cell culture and human tissue samples The OC cell lines SK-OV-3 (RRID: CVCL_0C84) and A2780 (RRID: CVCL_0134) and the normal ovarian epithelial cell line IOSE-80 (RRID: CVCL_5546) were purchased from Shanghai Zhongqiao Xinzhou Biotechnology Co. Ltd. (Shanghai, China). These cells were maintained in RPMI-1640 culture medium (Gibco, Baltimore, MD, USA) supplemented with 1% penicillin/streptomycin (Beyotime, Shanghai, China) and 10% fetal bovine serum (Procell, Wuhan, China). ES-2, another human OC cell line, was provided by Procell and cultured in a specialized complete medium from the same supplier. All cell lines were cultured at 37 °C with 5% CO2. The purity of these cell lines was confirmed using STR analysis. Tissue samples from normal ovarian tissues (n = 48) and OC tumors (n = 48) were collected from inpatients at the Second Affiliated Hospital of Harbin Medical University (Harbin, China). The clinical characteristics of 48 OC samples are listed in Table 1. The experimental protocol was approved by the Medical Ethics Committee of the Second Affiliated Hospital of Harbin Medical University (approval number: Ky2020-060), and all participants provided informed written consent. Table 1The clinical characteristics of patients with OCCharacteristicsNumberPercentageTotal48Age at surgery (years) < 604287.5% ≥ 60612.5%Histology type Serous2858.3% Mucinous1020.8% Endometrioid816.7% Other24.2%FIGO stage I + II1531.25% III + IV3368.75%Tumor size < 10 cm816.7% ≥ 10 cm4083.3%Lymph node metastasis Positive3470.8% Negative1429.2%Peritoneal cytology Positive3266.7% Negative1633.3% Table 1The clinical characteristics of patients with OCCharacteristicsNumberPercentageTotal48Age at surgery (years) < 604287.5% ≥ 60612.5%Histology type Serous2858.3% Mucinous1020.8% Endometrioid816.7% Other24.2%FIGO stage I + II1531.25% III + IV3368.75%Tumor size < 10 cm816.7% ≥ 10 cm4083.3%Lymph node metastasis Positive3470.8% Negative1429.2%Peritoneal cytology Positive3266.7% Negative1633.3% The clinical characteristics of patients with OC Measurement of METTL2B mRNA expression METTL2B mRNA expression was measured by qRT-PCR. Total RNA was extracted from samples using Trizol reagent (Invitrogen, Carlsbad, CA, USA), and cDNA was synthesized from 2 μg of total RNA. PCR was performed using the ChamQ SYBR qPCR Master Mix kit (Vazyme, Nanjing, China) on a QuantStudio Real-Time PCR system (Applied Biosystems, Foster City, CA, USA). The primer pair sequences were as follows:METTL2B forward primer, 5′-CACCTGCAATCCTCGCCGATAAG-3′; METTL2B reverse primer, 5′-GCTCTTCCGACCACTCCACATTG-3′; 18 s rRNA (used as a reference gene) forward primer, 5′-ATCCTCAGTGAGTTCTCCCG-3′; and 18 s rRNA reverse primer, 5′-CTTTGCCATCACTGCCATTA-3′. METTL2B forward primer, 5′-CACCTGCAATCCTCGCCGATAAG-3′; METTL2B reverse primer, 5′-GCTCTTCCGACCACTCCACATTG-3′; 18 s rRNA (used as a reference gene) forward primer, 5′-ATCCTCAGTGAGTTCTCCCG-3′; and 18 s rRNA reverse primer, 5′-CTTTGCCATCACTGCCATTA-3′. METTL2B forward primer, 5′-CACCTGCAATCCTCGCCGATAAG-3′; METTL2B reverse primer, 5′-GCTCTTCCGACCACTCCACATTG-3′; 18 s rRNA (used as a reference gene) forward primer, 5′-ATCCTCAGTGAGTTCTCCCG-3′; and 18 s rRNA reverse primer, 5′-CTTTGCCATCACTGCCATTA-3′. All primers were obtained from Sangon Biotech (Shanghai, China). METTL2B mRNA expression was normalized to 18 s rRNA and analyzed using the 2−ΔΔCT method. Silencing of endogenous METTL2B expression using siRNA To inhibit endogenous METTL2B expression, two siRNAs targeting METTL2B were designed and synthesized by RiboBio (Guangzhou, China): siRNA-1 (sequence: GATGGTACTTCTGCGAGAT) and siRNA-2 (sequence: CGAAGAGCCTTGAACATAA). When the cells reached 50%–60% confluency, they were transfected with METTL2B siRNAs using CALNPTM RNAi transfection reagent (D-nano Therapeutics, Beijing, China). The siRNA-transfected cells were harvested at 24 or 48 h post-transfection for functional studies. Stable silencing of METTL2B expression in OC cells To stably knockout METTL2B in A2780 cells, METTL2B lentiviral shRNA (shMETTL2B; sequence: AACAAGAGTGAAGTATGT) and its reference shNC (blank lentivirus) were designed and synthesized by GenePharma (Shanghai, China). After transducing shMETTL2B and shNC into cells (24 h), stably transduced cells were selected using 2 μg/mL puromycin for 2 weeks. The surviving cells were harvested, and their lysates were used for western blotting. Western blotting To determine the protein levels of METTL2B in human tissue samples and ovarian cell lines, lysates were prepared using RIPA buffer, and protein concentrations were quantified using the BCA protein assay (Beyotime). Proteins were separated by electrophoresis on a 12% SDS-PAGE gel, followed by transfer to a nitrocellulose membrane (Pall, Port Washington, NY, USA). After blocking the membrane at room temperature for 1 h, the blot was incubated overnight at 4 °C with primary antibodies against METTL2B and GAPDH (Proteintech, Rosemont, IL, USA), as well as p-mTOR (Ser2448), mTOR, AKT, and p-AKT (Ser473) from Cell Signaling Technology (Danvers, MA, USA). The target protein bands were visualized by incubating the membrane with an HRP-conjugated secondary antibody (ZSGB-BIO, Beijing, China) for 1 h and then briefly exposing the membrane to an ECL kit (Beyotime). Proliferation potential assessment The proliferation potential of human OC cell lines was assessed using the 5-ethynyl-2′-deoxyuridine (EdU) incorporation assay (Beyotime). Briefly, 10,000 OC cells were seeded into each well of a 24-well plate. The cells were cultured in medium containing 10 μM EdU for 2 h in an incubator. After incubation, the cells were fixed with 4% paraformaldehyde, permeabilized using 0.3% Triton X-100, and labeled with an anti-EdU working solution. Nuclei were also counterstained with Hoechst 33,342. The signals from the EdU-labeled cells were visualized and recorded using an inverted microscope (Olympus IX51). Colony formation assay After 24 h of siRNA transfection in A2780 and SK-OV-3 cells, the cells were trypsinized and seeded at a density of 500 cells per well in triplicate in six-well plates. The cells were cultured in a 37 °C incubator for 14 days until colonies formed. The colonies were then fixed with methanol and visualized by staining with crystal violet. Colonies containing more than 50 cells were counted to determine the efficiency of colony formation. Hematoxylin–eosin (HE) staining To examine histological changes in mouse tumor tissue samples, samples were fixed in 3.7% formalin, embedded in paraffin, and sliced into 5-μm-thick sections. The histological examination utilized various staining methods, including HE staining (Boster Biotech, Wuhan, China). Staining results were observed and recorded using a Zeiss Mirax Slide Scanner. Immunohistochemistry (IHC) The 5-μm-thick paraffin sections of tumor tissue were deparaffinized and hydrated using a xylene and graded ethanol series and subjected to antigen retrieval in boiled citrate buffer. Endogenous peroxidase activity was inhibited with 3% H2O2 (in methanol), and the samples were blocked with goat serum for 1 h. Following these steps, the sections were incubated overnight at 4 °C with primary antibodies against METTL2B (Proteintech) or Ki67 (ZSGB-BIO). The next day, the sections were washed with PBS and incubated with a secondary antibody (goat anti-rabbit IgG-HRP from ZSGB-BIO) for 1 h at room temperature. The IHC results were visualized using DAB reagent (ZSGB-BIO) and observed using a Zeiss Mirax Slide Scanner. The positive areas in the sections were quantified using ImageJ software. Transwell migration and invasion assays After 24 h of siRNA transfection, cells were trypsinized and seeded into the upper chambers of Transwell plates (Corning, NY, USA) or Matrigel-coated Transwell plates (BD Bioscience, San Jose, CA, USA). Each chamber contained 10,000 cells in 200 μL of serum-free medium. The upper chambers were equipped with an 8-μm pore membrane to permit cell migration or invasion. After incubation (during which the bottom chamber contained medium supplemented with 10% FBS), cells on the undersurface of the membrane were detected, and the number of migrating or invading cells was counted. Subsequently, the cells were stained with 0.1% crystal violet for visualization and quantification. OC xenograft animal model In our study, we developed an OC xenograft animal model by inoculating A2780-shNC or A2780-shMETTL2B cells subcutaneously into female BALB/c nude mice (4–6 weeks old) obtained from Changsheng Biotechnology (Shenyang, China). Each mouse received an injection of 5 × 106 cells into the dorsal skin (seven mice per group). Tumor volumes were measured every 3 days. Four weeks after cell inoculation, the nude mice were anesthetized with 250 mg/kg Avertin (intraperitoneal; MilliporeSigma, Burlington, MA, USA) and sacrificed by cervical dislocation. Then, tumors were dissected and photographed, and their weights were recorded. The experimental animals (SPF-grade) were bred and housed in the Animal Experiment Center of Harbin Medical University. Statistical analyses Data analysis in this study was performed using GraphPad Prism 9 (San Diego, CA, USA) and SPSS version 26.0. Statistical differences in continuous data between the groups were assessed using Student’s t-test or one-way ANOVA, whereas nonparametric data were analyzed using Spearman’s test. Furthermore, the diagnostic value of METTL2B in OC was evaluated using receiver operating characteristic (ROC) curve analysis. Statistical significance between groups was indicated by P < 0.05. Results Association of elevated METTL2B expression with poor prognosis in OC To investigate METTL2B expression in OC, RNA sequencing data were sourced from 427 OC samples within TCGA. Gene expression profiles for 88 normal ovarian samples were obtained from the GTEx Portal. Additionally, we utilized gene microarray profiling data (GSE54388) from GEO, which included 6 normal and 16 OC specimens. Our findings demonstrated that METTL2B expression was significantly elevated in OC samples compared with that in normal tissues (Fig. 1A–B). According to AUC value of 0.801, METTL2B expression can effectively distinguish between OC and normal ovarian tissues (Fig. 1C). Although the difference in PPS between the high and low METTL2B expression groups was not significant, high METTL2B expression tended to be correlated with shorter PFS and worse OS in patients with OC (Fig. 1D).Fig. 1High METTL2B expression in OC is correlated with poor prognosis. A Box plots presenting the comparative expression of METTL2B in OC (n = 426) and normal ovarian tissues (n = 88) using TCGA and GTEx. B METTL2B expression in healthy control (n = 6) and patient samples (n = 16) in GSE54388. C ROC curve analysis demonstrated the sensitivity and specificity of METTL2B in predicting OC prognosis. D Kaplan–Meier curves for PPS, OS, and PFS sourced from the GEPIA database. E Relative expression of METTL2B mRNA and protein in ovarian tissues from patients with OC (n = 48) and normal controls (n = 48) as measured by qRT-PCR and western blotting. F Relative expression of METTL2B mRNA and protein in A2780 and SK-OV-3 cells compared with that in IOSE-80 cells. All quantitative data (n = 3 per group) are presented as the mean ± SD. Each data point represents one independent biological replicate in the graph. *P < 0.05, **P < 0.01, ***P < 0.001, ns = not significant. Full-length blots/gels are presented in Supplementary Fig. 3 High METTL2B expression in OC is correlated with poor prognosis. A Box plots presenting the comparative expression of METTL2B in OC (n = 426) and normal ovarian tissues (n = 88) using TCGA and GTEx. B METTL2B expression in healthy control (n = 6) and patient samples (n = 16) in GSE54388. C ROC curve analysis demonstrated the sensitivity and specificity of METTL2B in predicting OC prognosis. D Kaplan–Meier curves for PPS, OS, and PFS sourced from the GEPIA database. E Relative expression of METTL2B mRNA and protein in ovarian tissues from patients with OC (n = 48) and normal controls (n = 48) as measured by qRT-PCR and western blotting. F Relative expression of METTL2B mRNA and protein in A2780 and SK-OV-3 cells compared with that in IOSE-80 cells. All quantitative data (n = 3 per group) are presented as the mean ± SD. Each data point represents one independent biological replicate in the graph. *P < 0.05, **P < 0.01, ***P < 0.001, ns = not significant. Full-length blots/gels are presented in Supplementary Fig. 3 Consistent with TCGA and GTEx results, METTL2B expression was notably elevated in surgically resected OC tissue samples and normal ovarian tissues (Fig. 1E, Supplementary Fig. S1). Similar trends were also evident when comparing the qRT-PCR and western blotting data between OC cells (A2780 and SK-OV-3) and normal ovarian cells (IOSE-80), as presented in Fig. 1F. The CNV characteristics of METTL2B in OC Genomic changes affect tumor development and immune tolerance. To explore the possible causes of METTL2B upregulation in OC, we analyzed CNV related to the METTL2B gene in OC. METTL2B is situated on the long arm of chromosome 6 at the q21 band. CNV analysis indicated that METTL2B amplification mutations were present in a majority of patients with OC, and whereas deletion of the METTL2B gene was rare (Fig. 2A). The amplified region encompasses the gene body of METTL2B and extends to neighboring sequences on chromosome 6q21. Additionally, a strong correlation between METTL2B mRNA expression and its gene copy number was revealed through correlation analysis (Fig. 2B). These results suggested that METTL2B gene amplification is a prominent mechanism underlying high METTL2B expression in OC.Fig. 2Evaluation of CNV of METTL2B in OC. A Evaluation of METTL2B CNVs in OC using the GSCA database. B Spearman correlation analysis indicating the relationship between METTL2B CNV and expression Evaluation of CNV of METTL2B in OC. A Evaluation of METTL2B CNVs in OC using the GSCA database. B Spearman correlation analysis indicating the relationship between METTL2B CNV and expression Enrichment of METTL2B-associated pathways in OC based on GO and KEGG analysis To investigate METTL2B-associated biological functions and pathways in OC, our research found 1605 genes positively correlated (r > 0.3, P < 0.05) with elevated METTL2B expression in TCGA database (Supplementary Table 1). GO analysis of METTL2B-associated 1605 genes highlighted their enrichment in various biological functions, including cytoplasmic ribonucleoprotein granule complexes, methyltransferase activity, chromosome condensation, ATP hydrolysis, DNA replication, RNA splicing, and RNA processing (Fig. 3A–C). A protein–protein interaction (PPI) network constructed using the GeneMANIA database identified the top 20 proteins that interact with METTL2B, including CENPU, MAPK3, METTL2A, NAT16, TPM3, AGK, TRUB2, CMC2, C5orf22, C1D, CSNK2A1, HSPA8, METTL8, METTL6, NSUN2, CCT7, SMG8, GATAD2B, SORCS3, and SLC35B4 (Fig. 3D).Fig. 3Enrichment analysis of METTL2B in OC and the associated PPI network. A–C Analysis of GO terms for 1605 genes positively correlated with METTL2B. A. Biological process; B. Molecular function; C. Cellular component. D A PPI network associated with METTL2B was generated using the GENEMANIA platform Enrichment analysis of METTL2B in OC and the associated PPI network. A–C Analysis of GO terms for 1605 genes positively correlated with METTL2B. A. Biological process; B. Molecular function; C. Cellular component. D A PPI network associated with METTL2B was generated using the GENEMANIA platform To identify potential pathways associated with METTL2B expression in OC, we used GSEA with KEGG and Reactome as pathway repositories. Through KEGG analysis, we identified several pathways significantly enriched in the high METTL2B expression group, including cell cycle, generation of basal transcription factors, nucleotide excision repair, and RNA degradation (Fig. 4A, Supplementary Table 2). Conversely, low METTL2B expression was significantly correlated with the following pathways: cytotoxicity by natural killer cells and antigen processing and presentation (Fig. 4B, Supplementary Table 2). The analysis based on Reactome indicated that the following pathways were enriched in the high METTL2B expression group: RNA metabolism, cell cycle, FGFR2, TGF-β receptor complex, and mTOR signaling (Fig. 4C and Supplementary Table 3). Conversely, the following pathways were enriched in the low METTL2B expression group: chemokine–chemokine receptor binding, endosomal vacuolar pathway, initial triggering of complement, and regulation of CD22-mediated BCR (Fig. 4D and Supplementary Table 3).Fig. 4Functional annotations comparing high and low METTL2B expression groups within TCGA cohort, as analyzed via GSEA. A-B KEGG pathways for the high METTL2B expression group (A) and low METTL2B expression group (B) using GSEA. C-D Reactome pathway analysis for the high METTL2B expression group (C) and low METTL2B expression group (D) using GSEA Functional annotations comparing high and low METTL2B expression groups within TCGA cohort, as analyzed via GSEA. A-B KEGG pathways for the high METTL2B expression group (A) and low METTL2B expression group (B) using GSEA. C-D Reactome pathway analysis for the high METTL2B expression group (C) and low METTL2B expression group (D) using GSEA Impact of METTL2B knockdown on oncogenic behaviors in OC: In vitro and in vivo models Because of the aberrant overexpression of METTL2B observed in OC cell lines and surgical specimens from patients with OC, understanding the underlying mechanisms is crucial. Thus, our study investigated the impact of METTL2B knockdown on oncogenic behaviors in OC. METTL2B expression was silenced using two specific siRNAs in A2780 and SK-OV-3 cells. Following METTL2B knockdown, both the mRNA and protein levels of METTL2B were significantly reduced compared with those in siNC-transfected control cells (Fig. 5A–B). Following METTL2B knockdown, we observed significant reductions in the proliferation, migration, and invasion capabilities of OC cells. This was evidenced by decreased colony formation potential (Fig. 5C), reduced EdU incorporation (Fig. 5D), and impaired migration and invasion (Fig. 5E).Fig. 5Impact of METTL2B silencing on malignant cellular behaviors in OC. A–B Analysis via qRT-PCR (A) and western blotting (B) illustrated METTL2B expression in A2780 and SK-OV-3 cells after transfection with siMETTL2B#1 and siMETTL2B#2 or control vectors. C–D Images and quantification of colony formation assays (C) and EdU incorporation assays (D) demonstrated cell proliferation potential in A2780 and SK-OV-3 cells 24 h post-transfection with siRNA (Scale bar: 200 µm). E Transwell assays used to assess the migration and invasion capabilities of OC cells (Scale bar: 100 μm, ** P < 0.01, *** P < 0.001). Full-length blots/gels are presented in Supplementary Fig. 3 Impact of METTL2B silencing on malignant cellular behaviors in OC. A–B Analysis via qRT-PCR (A) and western blotting (B) illustrated METTL2B expression in A2780 and SK-OV-3 cells after transfection with siMETTL2B#1 and siMETTL2B#2 or control vectors. C–D Images and quantification of colony formation assays (C) and EdU incorporation assays (D) demonstrated cell proliferation potential in A2780 and SK-OV-3 cells 24 h post-transfection with siRNA (Scale bar: 200 µm). E Transwell assays used to assess the migration and invasion capabilities of OC cells (Scale bar: 100 μm, ** P < 0.01, *** P < 0.001). Full-length blots/gels are presented in Supplementary Fig. 3 In addition to the observed positive results in the OC cell model, we further investigated the impact of METTL2B knockdown on oncogenic behaviors using an in vivo OC model. To achieve this, we established an OC xenograft animal model by subcutaneously inoculating A2780-shNC or A2780-shMETTL2B cells into female BALB/c nude mice (seven mice per group). Tumor volumes were measured every 3 days, and the mice were euthanized 4 weeks later. Tumors were dissected, photographed, and weighed. Our findings revealed significant reductions in tumor size and weight in the METTL2B-silenced groups compared with those in the control mice (Fig. 6A–B). Furthermore, IHC highlighted a decrease in Ki67 expression in the tumor areas of nude mice injected with A2780-shMETTL2B cells compared with the findings in mice injected with A2780-shNC cells (Fig. 6C). To verify the METTL2B shRNA efficiency, METTL2B protein expression was examined by western blotting in A2780-shMETTL2B cells (Fig. S2). Overall, our results underscore the oncogenic role of METTL2B in OC tumorigenesis.Fig. 6Suppression of tumor proliferation in vivo by stably silencing METTL2B. A Representative images of xenograft mice 28 days after transplantation (top panel) and measurements of tumor sizes (n = 7, bottom panel). B Weights of tumors extracted from mice. C Representative images of HE and IHC staining for Ki67 and METTL2B in xenograft tumor samples (left panel; scale bar, 1000 μm for shNC group and 500 μm for shMETTL2B group) and their respective quantifications (right panels; scale bar, 50 μm, * P < 0.05, *** P < 0.001) Suppression of tumor proliferation in vivo by stably silencing METTL2B. A Representative images of xenograft mice 28 days after transplantation (top panel) and measurements of tumor sizes (n = 7, bottom panel). B Weights of tumors extracted from mice. C Representative images of HE and IHC staining for Ki67 and METTL2B in xenograft tumor samples (left panel; scale bar, 1000 μm for shNC group and 500 μm for shMETTL2B group) and their respective quantifications (right panels; scale bar, 50 μm, * P < 0.05, *** P < 0.001) METTL2B silencing suppressed the AKT/mTOR pathway in OC Based on prior bioinformatics analysis, elevated METTL2B expression was found to be correlated with activation of the mTOR signaling pathway. It has been demonstrated that dysregulation of the PI3K/AKT signaling pathway, in which mTOR acts as a crucial kinase downstream, is correlated with progression and drug resistance in OC [29, 30]. To explore the relationship of METTL2B with the AKT/mTOR pathway, we conducted western blotting. Following METTL2B silencing in both A2780 and SK-OV-3 cells, we assessed the expression of p-AKT (Ser473), p-mTOR (Ser2448), total AKT. and total mTOR. Western blotting demonstrated that p-AKT (Ser473) expression, but not total AKT expression, was significantly decreased in both cell lines following METTL2B knockdown. We also observed a significant decrease in p-mTOR (Ser2448) expression, but not total mTOR expression, in both cell lines upon METTL2B silencing (Fig. 7A). In addition, the ratios of p-AKT/AKT and p-mTOR/mTOR in mouse tumor tissue samples were examined using western blotting, revealing similar results to those observed in the cell model (Fig. 7B).Fig. 7Inhibition of malignant progression in OC cells through METTL2B silencing and suppression of the AKT/mTOR signaling pathway. A Western blotting demonstrating the inhibition of AKT/mTOR pathway activity in A2780 and SKOV3 cells following METTL2B siRNA transfection. B Western blotting revealing the inhibition of AKT/mTOR pathway activity in A2780-shMETTL2B mice in comparison to A2780-shNC mice (*P < 0.05, **P < 0.01, ***P < 0.001, ns = not significant). Full-length blots/gels are presented in Supplementary Fig. 3 Inhibition of malignant progression in OC cells through METTL2B silencing and suppression of the AKT/mTOR signaling pathway. A Western blotting demonstrating the inhibition of AKT/mTOR pathway activity in A2780 and SKOV3 cells following METTL2B siRNA transfection. B Western blotting revealing the inhibition of AKT/mTOR pathway activity in A2780-shMETTL2B mice in comparison to A2780-shNC mice (*P < 0.05, **P < 0.01, ***P < 0.001, ns = not significant). Full-length blots/gels are presented in Supplementary Fig. 3 Immune characteristics of METTL2B in OC To explore the interplay between METTL2B and the TME, we utilized the ESTIMATE algorithm to calculate ESTIMATE scores across TCGA-OC samples, for which the levels of infiltrating stromal and immune cells were predicted according to gene signatures. Our analysis revealed that METTL2B expression was negatively correlated with the stromal (r = − 0.143), immune (r = − 0.301), and ESTIMATE scores (r = − 0.246, Fig. 8A–C).Fig. 8Analysis of immune infiltration. A–C Spearman correlation analysis illustrating the relationships of METTL2B expression with stromal (A), immune (B), and ESTIMATE scores (C). D Lollipop chart presenting the correlation of METTL2B expression with infiltration of 24 different immune cell types. *P < 0.05, **P < 0.01, ***P < 0.001, ns = not significant Analysis of immune infiltration. A–C Spearman correlation analysis illustrating the relationships of METTL2B expression with stromal (A), immune (B), and ESTIMATE scores (C). D Lollipop chart presenting the correlation of METTL2B expression with infiltration of 24 different immune cell types. *P < 0.05, **P < 0.01, ***P < 0.001, ns = not significant Further investigation using ssGSEA highlighted a complex relationship between METTL2B expression and immune cell infiltration. Specifically, METTL2B expression was positively correlated with infiltrating immune cells, such as Tcm and helper T cells, but negatively correlated with the infiltration scores of multiple immune cells, including cytotoxic cells, T cells, CD56dim NK cells, activated dendritic cells (aDCs), helper follicular T cells (Tfh), Th1 cells, immature dendritic cells (iDCs), CD8+ T cells, CD56bright NK cells, dendritic cells, regulatory T cells, mast cells, macrophages, B cells, neutrophils, Th17 cells, eosinophils, and γδ T cells (Fig. 8D). Exploring single-cell gene expression in the TME To analysis the relationship between METTL2B and the TME, a single-cell gene expression dataset (TISCH2) was used in our research. We leveraged TISCH2 and selected GSE17048, focusing on six patients with OC and omental metastasis (Supplementary Table 4). Through clustering analysis, we categorized the single-cell samples into 25 distinct clusters (Fig. 9A). Subsequently, these clusters were annotated into 10 cell types, encompassing proliferating T cells, plasma cells, myofibroblasts, monocytes or macrophages, malignant cells, endothelial cells, CD8 T cells, conventional CD4 T cells, and B cells (Fig. 9B). Each patient with OC exhibited a unique distribution of these 10 cell types (Fig. 9C). Notably, METTL2B expression was prominently elevated in malignant cells compared with the findings in the other identified cell types (Fig. 9D).Fig. 9Single-cell transcriptomic analysis of METTL2B expression across various cell types in the TME. A–B Identification and analysis of cell clusters (A) and cell types (B) in the GSE147082 dataset. C Proportional composition of cell types in each patient sample. D METTL2B expression across different cell types according to GSE147082 Single-cell transcriptomic analysis of METTL2B expression across various cell types in the TME. A–B Identification and analysis of cell clusters (A) and cell types (B) in the GSE147082 dataset. C Proportional composition of cell types in each patient sample. D METTL2B expression across different cell types according to GSE147082 Impact of METTL2B expression on anticancer drug sensitivity To explore the relationship between METTL2B expression and the susceptibility to anticancer therapeutic agents, we utilized the CellMiner database to identify seven drugs significantly correlated with METTL2B expression. As depicted in Fig. 10, METTL2B was positively correlated with the susceptibility to calusterone, XL-147, vismodegib, vorinostat, fenretinide, nelarabine, and testolactone.Fig. 10Correlation between METTL2B expression and sensitivity to various anticancer drugs as analyzed using the CellMiner database Correlation between METTL2B expression and sensitivity to various anticancer drugs as analyzed using the CellMiner database Discussion OC is the most fatal gynecological malignancy [31, 32]. Early detection continues to be a major hurdle, as nearly half of all patients with OC are diagnosed at advanced stages, frequently presenting with metastases dispersed throughout the peritoneal cavity. Consequently, the prognosis and OS rates for these patients are typically dismal [33, 34]. In response, there has been a shift toward molecular targeted epigenetic therapies, which consider the varied epidemiological and genomic characteristics of different OC tissue types [35]. Among epigenetic modifications, the m6A modification is particularly notable for its regulatory role in gene transcription, influencing OC progression and resistance to treatment. Furthermore, therapies targeting m6A regulatory factors have displayed promise in enhancing the tumor-suppressive effects of chemotherapy [36, 37]. The m3C modification is frequently found in the anticodon loop at position 32 of certain eukaryotic cytoplasmic and mammalian mitochondrial tRNAs, including tRNAThr, tRNASer, and some tRNAArg species. To date, research has only identified the specific methyltransferases that catalyze the m3C modification at this position in eukaryotic cytoplasmic tRNAThr, tRNASer, and tRNAArg [20, 38–40]. Among mammals, enzymes such as METTL2, METTL6, and METTL8 are recognized for their m3C activity. METTL2A and METTL2B, which are closely related variants of METTL2 differing by only six amino acids, have been extensively studied [20]. However, investigations revealed that the m3C32 modification activity of METTL2B is significantly weaker than that of METTL2A in vitro [41]. Previous research revealed a uniform expression pattern for the four m3C-associated genes (METTL2A, METTL2B, METTL6, METTL8) across various cancer types, including hepatocellular carcinoma, esophageal carcinoma, colon adenocarcinoma, endocervical adenocarcinoma, and cervical squamous cell carcinoma [21, 23, 42]. These findings suggest that these genes function as oncogenes in these malignancies. In our research, we specifically examined METTL2B and its oncogenic roles in OC, offering new insights into its potential mechanisms in promoting OC development. Our analyses, utilizing data from TCGA, GTEx, and GEO databases, demonstrated for the first time that METTL2B expression is significantly higher in OC tumor samples than in normal ovarian tissue. Furthermore, the AUC of METTL2B in OC reached 0.801, underscoring its substantial diagnostic potential for distinguishing between tumor and normal tissues. It is important to note that patients with OC and high METTL2B expression exhibited shorter PFS. The results of qRT-PCR and western blotting confirmed the remarkable overexpression of the METTL2B gene in both OC surgical specimens and two human OC cell lines, consistent with our bioinformatics results. Further studies indicated that the increased expression of METTL2B in OC might result from amplification mutations, as detailed in the GSCA database. The molecular and biological properties of METTL2B in OC were deliberately investigated through GO and KEGG enrichment analyses, highlighting METTL2B-associated critical biological functions and pathways, such as RNA metabolism, cell cycle regulation, FGFR2 signaling, TGF-β receptor complex signaling, and the mTOR signaling pathway. In particular, the AKT/mTOR signaling pathway is known to play a pivotal role in OC progression, contributing to tumor growth, cancer cell migration and invasion, and heightened resistance to chemoradiotherapy [10]. Further exploration of METTL2B’s oncogenic effects was conducted using in vitro and in vivo models. The results demonstrated that METTL2B knockdown could significantly curtail oncogenic behaviors in OC cells, including aspects such as proliferation, migration, and invasion. Additionally, this intervention led to a marked reduction in the activity of p-AKT (Ser473) and p-mTOR (Ser2448). These results suggest that METTL2B, acting as an oncogene, could be a valuable indicator for OC diagnosis and prognosis prediction. Nevertheless, the specific molecular mechanisms by which METTL2B influences the m3C modification in cancer development and progression are yet to be fully determined. A growing body of research has linked tumor immune infiltration to patient prognosis across various cancers. However, the role of METTL2B within the TME of OC was not previously documented. Our investigation delved into the immune properties of METTL2B in OC, assessing factors such as immune cell infiltration and single-cell type annotation within the TME. Our findings revealed inverse relationships of METTL2B expression with stromal, immune, and ESTIMATE scores. We observed a positive association between METTL2B expression and the infiltration of Tcm and helper T cells. However, METTL2B expression was negatively associated with the infiltration of various immune cells, including Tfh cells, Tfh cells, Th1 cells, iDCs, CD8+ T cells, CD56bright NK cells, regulatory T cells, macrophages, and B cells. It has been reported that tumor-infiltrating lymphocytes (TILs) in the TME are associated with better outcomes in OC [43]. Recent studies indicated that in high-grade serous carcinoma (HGSC), a high proportion of CD56brightCD16− NK cells in the ascites is associated with extended PFS and OS, whereas a high macrophage count was correlated only with improved OS. This suggests that METTL2B overexpression suppresses the immune activity of tumor-infiltrating cells, potentially accelerating the progression and severity of OC. On the contrary, elevated METTL2B expression could suppress the cytotoxic effects of TILs on tumors and reduce OC [44]. Additionally, a close relationship between METTL2B expression and susceptibility to chemotherapeutic agents was validated in this research based on drug sensitivity analysis, underscoring the potential of METTL2B as a therapeutic target for OC. These findings collectively underscore the significant link between METTL2B expression and tumor immunity in OC. Conclusions In conclusion, our study demonstrated that METTL2B expression is significantly elevated in OC, and this elevation is associated with decreased PFS. Silencing METTL2B was found to inhibit the malignant progression of OC by reducing AKT/mTOR signaling activity. Additionally, METTL2B appears to influence immune cell infiltration within the TME. Collectively, these results indicate that METTL2B might function as an oncogene, playing a crucial role in the malignant progression and interacting with the TME in OC. Supplementary Information Supplementary Material 1.Supplementary Material 2.Supplementary Material 3.Supplementary Material 4.Supplementary Material 5.Supplementary Material 6. Supplementary Material 1. Supplementary Material 2. Supplementary Material 3. Supplementary Material 4. Supplementary Material 5. Supplementary Material 6.